Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 07, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,129.49 pence per share.
Material Changes
- Share Repurchase: The Company purchased 1,350,000 Ordinary shares of 25 pence each on April 07, 2008.
- Share Cancellation: The repurchased shares were cancelled immediately following the transaction.
- Treasury Holdings: Post-cancellation, the Company holds 484,194,158 shares in Treasury, representing 8.95% of total voting rights.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) is 5,411,994,892.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,411,994,892) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on total voting rights (8.95%).
- Review the specific price paid for the repurchase (1,129.49 pence) against market prices on April 07, 2008.